Marc Humbert

发表

Targeting of c-kit+ haematopoietic progenitor cells prevents hypoxic pulmonary hypertension

M. Humbert, F. Perros, G. Simonneau, 2010, European Respiratory Journal.

Treatment of pulmonary arterial hypertension with targeted therapies

M. Humbert, X. Jaïs, L. Savale, 2011, Nature Reviews Cardiology.

Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension

C. Munaut, M. Humbert, E. Fadel, 2005, European Respiratory Journal.

Treatment of pulmonary arterial hypertension.

M. Humbert, X. Jaïs, G. Simonneau, 2004, The New England journal of medicine.

Inflammation in pulmonary arterial hypertension.

M. Humbert, F. Perros, D. Montani, 2012, Chest.

IgG from patients with pulmonary arterial hypertension and/or systemic sclerosis binds to vascular smooth muscle cells and induces cell contraction

M. Humbert, L. Mouthon, G. Simonneau, 2011, Annals of the rheumatic diseases.

Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension

M. Humbert, E. Fadel, S. Eddahibi, 2007, European Respiratory Journal.

Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension

M. Humbert, J. Fermanian, L. Mouthon, 2006, European Respiratory Journal.

Chemokine macrophage inflammatory protein-1alpha mRNA expression in lung biopsy specimens of primary pulmonary hypertension.

M. Humbert, G. Simonneau, D. Émilie, 1998, Chest.

Endothelial-to-Mesenchymal Transition in Pulmonary Hypertension

E. Fadel, C. Péchoux, F. Perros, 2015 .

Endothelial-to-Mesenchymal Transition in Pulmonary Hypertension

E. Fadel, C. Péchoux, F. Perros, 2015 .

Endothelial-to-Mesenchymal Transition in Pulmonary Hypertension

E. Fadel, C. Péchoux, F. Perros, 2015 .

Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension

X. Jaïs, G. Simonneau, D. Montani, 2014 .

Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension

X. Jaïs, G. Simonneau, D. Montani, 2014 .

Recent Advances in Pulmonary Hypertension

M. Humbert, X. Jaïs, G. Simonneau, 2014 .

Bone morphogenetic protein signalling in heritable versus idiopathic pulmonary hypertension

M. Humbert, P. Dartevelle, E. Fadel, 2009, European Respiratory Journal.

Treatment of pulmonary arterial hypertension.

M. Humbert, G. Simonneau, O. Sitbon, 2004, The New England journal of medicine.

Primary pulmonary hypertension associated with the use of fenfluramine derivatives.

M. Humbert, G. Simonneau, O. Sitbon, 1998, Chest.

KCNK3 channel is important for the ventilatory response to hypoxia in rats

D. Montani, F. Antigny, C. Yegen, 2023, Respiratory Physiology & Neurobiology.

Pulmonary arterial hypertension and type-I glycogen-storage disease: the serotonin hypothesis

M. Humbert, R. Trembath, J. Launay, 2002, European Respiratory Journal.

IMPACT OF INITIATION OF BALLOON PULMONARY ANGIOPLASTY PROGRAM ON REFERRAL OF PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION TO SURGERY

M. Humbert, E. Fadel, X. Jaïs, 2018 .

Basic and translational research

A. Yaici, M. Tamby, G. Bussone, 2011 .

Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension.

M. Humbert, G. Simonneau, J. Dall'ava-Santucci, 1998, American journal of respiratory and critical care medicine.

[Investigation of pulmonary hypertension].

M. Humbert, G. Simonneau, D. Montani, 2008, Revue de pneumologie clinique.

Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects

M. Humbert, L. Iserin, G. Simonneau, 2006, European journal of clinical investigation.

Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension

M. Humbert, D. Chemla, G. Simonneau, 2006, European Respiratory Journal.

Current management approaches to portopulmonary hypertension

X. Jaïs, L. Savale, D. O’Callaghan, 2011, International journal of clinical practice. Supplement.

Klippel-Trenaunay syndrome as a rare cause of chronic thromboemboembolic pulmonary hypertension.

M. Humbert, E. Fadel, X. Jaïs, 2019, Respiratory medicine and research.

Treatment of severe pulmonary hypertension secondary to connective tissue diseases with continuous IV epoprostenol (prostacyclin).

M. Humbert, G. Simonneau, O. Sitbon, 1998, Chest.

Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease

M. Humbert, E. Fadel, X. Jaïs, 2009, European Respiratory Journal.

M. Humbert, K. Stenmark, X. Jaïs, 2015 .

Evidence of endogenous volatile organic compounds as biomarkers of diseases in alveolar breath.

S. Cohen-Kaminsky, E. Postaire, P. Stevens, 2013, Annales pharmaceutiques francaises.

Evidence and unresolved questions in pulmonary hypertension: Insights from the 5th French Pulmonary Hypertension Network Meeting.

X. Jaïs, L. Savale, O. Sitbon, 2024, Respiratory medicine and research.

Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first-line oral bosentan compared with an historical cohort of patients started on i.v. epoprostenol

D. Badesch, G. Simonneau, M. Rainisio, 2005 .

Implementing the ESC/ERS pulmonary hypertension guidelines: real-life cases from a national referral centre

M. Humbert, X. Jaïs, L. Savale, 2009, European Respiratory Review.